search
Back to results

Precision Exercise to Improve Outcomes in Sepsis (PRECISE)

Primary Purpose

Sepsis

Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
12-week precision exercise training
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Sepsis focused on measuring Sepsis, Exercise Tolerance, Exercise Training

Eligibility Criteria

19 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Signed informed consent At least 19 years of age ≥60 days prior to study enrollment, known or suspected infection that includes at least two of the following clinical criteria that together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate >22breaths/min, altered mentation, or systolic blood pressure <100mmHg. Cardiorespiratory fitness <80% of age and sex-predicted norms Can commit to attending 3 exercise sessions a week for 12-weeks Exclusion Criteria: Unable to provide informed consent On supplemental oxygen Known previous cardiac or cerebral vascular events in the past 90 days Diabetes Autoimmune diseases or on daily immunomodulatory drugs Obstructive sleep apnea Uncontrolled hypertension Known pregnancy/ intending to get pregnant within 28 days of enrolling in the study or breastfeeding Desaturation during exercise SpO2<85% Cardiovascular contraindication or musculoskeletal limitations to exercise as assessed during the cardiopulmonary exercise test

Sites / Locations

  • St. Paul's Hospital - Centre for Heart Lung InnovationRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Exercise Intervention

Attention Control

Arm Description

Patients will participate in a 12-week (36 sessions) precision exercise training intervention

Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.

Outcomes

Primary Outcome Measures

Change in constant load exercise time
Individuals will complete a constant-load exercise trial to symptom limitation at ~70% workload maximum (determined by a cardiopulmonary exercise test) on a cycle ergometer pre to post 12-weeks of the intervention period. The primary outcome will be change in time from pre to post test.

Secondary Outcome Measures

Change in health related quality of life (SF-36)
The change in health related quality of life measured by the SF-36 component scores pre to post 12-weeks of the intervention period. The SF 36 Medical Outcomes Study Survey (SF-36) is a 36-item survey that measures quality of life over eight domains, including physical functioning, bodily pain, limitations due to physical health problems, limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. Pre-coded numeric values are assigned to each scale, with items scored from 0-100. High scores represent a more favourable health state. Items in each domain are also averaged to create eight separate domain scores.

Full Information

First Posted
March 1, 2023
Last Updated
May 8, 2023
Sponsor
University of British Columbia
Collaborators
Vancouver Coastal Health Research Institute, Simon Fraser University, St. Paul's Hospital, Canada, Providence Health & Services
search

1. Study Identification

Unique Protocol Identification Number
NCT05784740
Brief Title
Precision Exercise to Improve Outcomes in Sepsis
Acronym
PRECISE
Official Title
Precision Exercise to Improve Patient Outcomes in Sepsis Survivors: PRECISE Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
April 17, 2023 (Actual)
Primary Completion Date
March 2025 (Anticipated)
Study Completion Date
August 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of British Columbia
Collaborators
Vancouver Coastal Health Research Institute, Simon Fraser University, St. Paul's Hospital, Canada, Providence Health & Services

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this interventional clinical research study is to assess the efficacy of a 12-week precision exercise training intervention to improve exercise tolerance in sepsis survivors. The main question it aims to answer is does a 12-week precision exercise training program improve constant load exercise time in sepsis survivors? Participants will: Answer questionnaires related to patient reported outcomes and give a blood sample Perform a constant load exercise test Complete 12-weeks (3 x per week, 36 session in total) of precision exercise training consisting of individualized, nonlinear periodized strength and aerobic exercise training. Researchers will compare the exercise group to an attention control group of sepsis survivors who do not receive exercise training but instead undergo usual care procedures and receive general lifestyle advice 1x per week.
Detailed Description
Sepsis is a life threatening condition that results in multi-organ system dysfunction. In those who survive sepsis, many patients present with chronic immune dysregulation (i.e., paradoxical hyperinflammation and immune suppression), leading to high rates of re-hospitalization. In addition, exercise tolerance is significantly reduced both acutely post hospital discharge and long term (~5 years post initial infection). Exercise training is a pleiotropic intervention that has been demonstrated to improve exercise tolerance in a multitude of clinical populations. Aerobic exercise training is also associated with anti-inflammatory and immune-enhancing effects; however, the magnitude of these immunological adaptations is largely dependent on the exercise prescription used. To date, exercise training studies in sepsis have used a more traditional generic linear exercise training approach, which has resulted in minimal or no effect on exercise tolerance. This is in contrast to other clinical populations wherein precision exercise training (e.g., individualized, nonlinear periodized, combined aerobic and strength training) has resulted in greater improvements in exercise tolerance compared to non-specific linear exercise programs, and is considered safe and tolerable. To date, no study has sought to investigate the effects of a precision exercise training intervention on exercise tolerance and immune function in sepsis survivors.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis
Keywords
Sepsis, Exercise Tolerance, Exercise Training

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Investigator
Allocation
Randomized
Enrollment
32 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise Intervention
Arm Type
Experimental
Arm Description
Patients will participate in a 12-week (36 sessions) precision exercise training intervention
Arm Title
Attention Control
Arm Type
No Intervention
Arm Description
Patients will not receive exercise training but will be contacted 1x per week via phone to document self-reported physical activity and general wellbeing.
Intervention Type
Other
Intervention Name(s)
12-week precision exercise training
Intervention Description
The 12-week exercise intervention will consist of both aerobic and strength exercise training performed 3x per week using an individualized and nonlinear periodized approach.
Primary Outcome Measure Information:
Title
Change in constant load exercise time
Description
Individuals will complete a constant-load exercise trial to symptom limitation at ~70% workload maximum (determined by a cardiopulmonary exercise test) on a cycle ergometer pre to post 12-weeks of the intervention period. The primary outcome will be change in time from pre to post test.
Time Frame
12-weeks
Secondary Outcome Measure Information:
Title
Change in health related quality of life (SF-36)
Description
The change in health related quality of life measured by the SF-36 component scores pre to post 12-weeks of the intervention period. The SF 36 Medical Outcomes Study Survey (SF-36) is a 36-item survey that measures quality of life over eight domains, including physical functioning, bodily pain, limitations due to physical health problems, limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue and general health perceptions. Pre-coded numeric values are assigned to each scale, with items scored from 0-100. High scores represent a more favourable health state. Items in each domain are also averaged to create eight separate domain scores.
Time Frame
12-weeks
Other Pre-specified Outcome Measures:
Title
Change in clinical biomarkers of immune function (highly sensitive C-reactive protein)
Description
The change in highly sensitive C-reactive protein (mg/L) pre to post 12-weeks of the intervention period.
Time Frame
12-weeks
Title
Change in clinical biomarkers of immune function (absolute lymphocyte count)
Description
The change in absolute lymphocyte count (per mL) pre to post 12-weeks of the intervention period.
Time Frame
12-weeks
Title
Change in clinical biomarkers of immune function (monocyte HLA-DR)
Description
The change in monocyte human leukocyte antigen-DR (per cell) pre to post 12-weeks of the intervention period.
Time Frame
12-weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signed informed consent At least 19 years of age ≥60 days prior to study enrollment, known or suspected infection that includes at least two of the following clinical criteria that together constitute a new bedside clinical score termed quickSOFA (qSOFA): respiratory rate >22breaths/min, altered mentation, or systolic blood pressure <100mmHg. Cardiorespiratory fitness <80% of age and sex-predicted norms Can commit to attending 3 exercise sessions a week for 12-weeks Exclusion Criteria: Unable to provide informed consent On supplemental oxygen Known previous cardiac or cerebral vascular events in the past 90 days Diabetes Autoimmune diseases or on daily immunomodulatory drugs Obstructive sleep apnea Uncontrolled hypertension Known pregnancy/ intending to get pregnant within 28 days of enrolling in the study or breastfeeding Desaturation during exercise SpO2<85% Cardiovascular contraindication or musculoskeletal limitations to exercise as assessed during the cardiopulmonary exercise test
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Graeme Koelwyn, PhD
Phone
604-682-2344
Ext
66221
Email
graeme.koelwyn@hli.ubc.ca
First Name & Middle Initial & Last Name or Official Title & Degree
John Boyd, MD
Phone
604-682-2344
Ext
63047
Email
john.boyd@hli.ubc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Graeme Koelwyn, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Paul's Hospital - Centre for Heart Lung Innovation
City
Vancouver
State/Province
British Columbia
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Graeme Koelwyn, PhD
Phone
604-682-2344
Ext
66221
Email
graeme.koelwyn@hli.ubc.ca
First Name & Middle Initial & Last Name & Degree
John Boyd, MD
Phone
604-682-2344
Ext
63047
Email
john.boyd@hli.ubc.ca
First Name & Middle Initial & Last Name & Degree
Graeme Koelwyn, PhD
First Name & Middle Initial & Last Name & Degree
John Boyd, MD
First Name & Middle Initial & Last Name & Degree
Neil Eves, PhD

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Deidentified individual participant data will be made available as required by a condition of awards and agreements supporting the research.
IPD Sharing Time Frame
12 months after publication and for up to 36 months post publication
IPD Sharing Access Criteria
The investigator who proposed to use the data and upon reasonable request. Requests should be directed to graeme.koelwyn@hli.ubc.ca. To gain access, data requestors will need to sign a data access agreement.

Learn more about this trial

Precision Exercise to Improve Outcomes in Sepsis

We'll reach out to this number within 24 hrs